Ntla stock forecast.

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools. Identify stocks that meet your criteria using seven unique stock screeners.

Ntla stock forecast. Things To Know About Ntla stock forecast.

May 4, 2023 · As for financials, the company’s top line and bottom line beat Street forecasts while its cash, cash equivalents, and marketable securities stood at $1.2B at the end of the quarter compared to ... NTLA Stock Price Performance Analysis. Depending on how one views it, the stock price performance for the year has been a mixed bag, resulting in either an optimistic or pessimistic outlook. Until today this year the stock’s price performance recorded a decrease of -15.08%. However, over the last six months, the performance has been …See Intellia Therapeutics, Inc. (NTLA) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.Oct 6, 2020 · For Intellia Therapeutics stock forecast for 2023, 2 predictions are offered for each month of 2023 with average Intellia Therapeutics stock forecast of $23.66, a high forecast of $23.9, and a low forecast of $23.43. The average Intellia Therapeutics stock forecast 2023 represents a 2.17% increase from the last price of $23.1599998474121.

The latest Intellia Therapeutics stock prices, stock quotes, news, and NTLA history to help you invest and trade smarter. ... The 61 analysts offering price forecasts for Intellia Therapeutics ... Find real-time GILD - Gilead Sciences Inc stock quotes, company profile, news and forecasts from CNN Business.Intellia Therapeutics Stock Price Prediction 2023, 2024, 2025. Moderna Price Prediction Tomorrow & Month. In 2 weeks Intellia Therapeutics stock prediction on Thursday, December, 14: 34.04 dollars, maximum 36.76, minimum 31.32. Intellia Therapeutics stock price forecast on Friday, December, 15: 34.21 dollars, maximum …

The Intellia Therapeutics Inc stock price gained 2.54% on the last trading day (Friday, 24th Nov 2023), rising from $30.26 to $31.03. During the last trading day the stock fluctuated 5.87% from a day low at $30.13 to a day high of $31.90. The price has risen in 6 of the last 10 days and is up by 24.32% over the past 2 weeks.Intellia Therapeutics Inc’s Stock Price as of Market Close. As of March 22, 2023, 4:00 PM CST, Intellia Therapeutics Inc’s stock price was $37.15. Intellia Therapeutics Inc is down 6.63% from its previous closing price of $39.79. During the last market session, Intellia Therapeutics Inc’s stock traded between $38.25 and $39.94.

Intellia Therapeutics (NTLA 2.54%) works in the up-and-coming area of gene editing. Invitae ( NVTA -0.52% ) specializes in genetic testing. Both stocks have declined over the past year.Intellia Therapeutics surged to the top spot among CRISPR stocks in 2021. The company and its partner, Regeneron ( REGN 0.93% ), announced impressive interim results in June 2021 from a phase 1 ...Track Intellia Therapeutics Inc (NTLA) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsFind real-time NTLA - Intellia Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business.

The average Editas Medicine stock forecast 2024 represents a 3.79% increase from the last price of $10.5299997329712. For Editas Medicine stock forecast for 2025, 12 predictions are offered for each month of 2025 with average Editas Medicine stock forecast of $10.98, a high forecast of $12.02, and a low forecast of $10.15.

Find the latest Intellia Therapeutics, Inc. NTLA analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range. investment rating.

Intellia Therapeutics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. ... Stock Price Target NTLA. High $ 145.00: Median $ 72.00: Low $ 29.00: Average $ 76.00: Current ...Find the latest Intellia Therapeutics, Inc. NTLA analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range …It's typically categorized as a valuation metric and is most often quoted as Cash Flow per Share and as a Price to Cash flow ratio. In this case, it's the cash flow growth that's being looked at ...Intellia's Q1 2023 financial report shows a cash position of $1.2 billion, with collaboration revenue rising to $12.6 million and a net loss of $103.1 million. The success of NTLA-2002 in further ...While NTLA stock may have its naysayers, so far, Wall Street analysts strongly support it. Presently, analysts peg Intellia shares as a consensus strong buy. Also, their average price target ...It's typically categorized as a valuation metric and is most often quoted as Cash Flow per Share and as a Price to Cash flow ratio. In this case, it's the cash flow growth that's being looked at ...

Intellia Therapeutics (NTLA) Receives a Buy from Stifel Nicolaus. Stifel nicolaus analyst dae gon ha maintained a buy rating on intellia therapeutics (ntla) on november 10. Gon ha covers the healthcare sector and has an average return of -5.4% and a 31.07% success rate on recommended stocks. The company's shares closed last friday at $24.13.Intellia Therapeutics Inc’s Stock Price as of Market Close. As of March 22, 2023, 4:00 PM CST, Intellia Therapeutics Inc’s stock price was $37.15. Intellia Therapeutics Inc is down 6.63% from its previous closing price of $39.79. During the last market session, Intellia Therapeutics Inc’s stock traded between $38.25 and $39.94.Apr 21, 2023 · (See NTLA stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy , a newly launched tool that unites all of TipRanks’ equity insights. Three Fool.com contributors identified what they believe could be monster stocks in the making. Here's why these chose Axsome Therapeutics ( AXSM 0.90%), CRISPR Therapeutics ( CRSP -3.42%), and ...Weather forecasts play an essential role in our daily lives, helping us plan our activities and stay prepared for any weather conditions that may come our way. One of the most common types of forecasts is the 7-day weather forecast, which p...Find the latest Intellia Therapeutics, Inc. (NTLA) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo FinanceFind real-time NTLA - Intellia Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business.

NTLA Revenue (Quarterly) data by YCharts. More than $1 billion in cash At the same time, though, Intellia reported $1.1 billion in cash during its most recent earnings call and about $200 million ...The global Phase 3 study of NTLA-2001, an in vivo CRISPR-based gene editing candidate, is anticipated to initiate by year-end 2023. "The FDA clearance of the NTLA-2001 IND application allows us to initiate a pivotal Phase 3 trial in the United States, marking the first in vivo CRISPR-based candidate to begin late-stage clinical development.

Nowadays finding high-quality stock photos for personal or commercial use is very simple. You just need to search the photo using a few descriptive words and let Google do the rest of the work.Track Intellia Therapeutics Inc (NTLA) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsNTLA Stock 12 Months Forecast. Based on 19 Wall Street analysts offering 12 month price targets for Intellia Therapeutics in the last 3 months. The average price target is $78.65 with a high forecast of $136.00 and a low forecast of $31.00. The average price target represents a 151.68% change from the last price of $31.25.The anecdotal wisdom is that the way to outperform the market this year has been to flock to the Magnificent Seven stocks (AAPL, AMZN, Google, META, MSFT, Latest NewsA high-level overview of Intellia Therapeutics, Inc. (NTLA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Three Fool.com contributors have identified beaten-down stocks of relatively small companies that could soar this year. Here's why they picked CRISPR Therapeutics ( CRSP 4.39%), Exelixis ( EXEL 0. ...

Predicting the weather has long been one of life’s great mysteries — at least for regular folks. Over the years, you’ve probably encountered a few older adults — maybe even your own grandparents — who made some weather predictions based on ...

See Intellia Therapeutics, Inc. (NTLA) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.

The race to develop a new gene therapy with CRISPR took some interesting turns recently. On the same day that Intellia Therapeutics (NTLA-1.23%) dazzled the medical community with clinical trial ...Throughout the U.S., the weather can be quite unpredictable, even with state-of-the-art radar, sensors and computer modeling technology right at meteorologists’ fingertips. The Old Farmer’s Almanac first provided valuable statistics and dat...Dec 1, 2023 · NTLA is a biotech company that develops gene editing therapies for cancer and other diseases. The average price target for its stock is $82.19, with a range of $40 to $144, based on 21 analyst recommendations. The stock has a strong buy rating from 18 brokerage firms and a low of 40.00. The upside is 237.12%. As the old saying goes, “Forewarned is forearmed.” This sentiment holds true when it comes to weather forecasting as well. One of the primary advantages of a 30-day extended weather forecast is the ability to plan ahead with confidence.Analyst Forecast According to 21 analysts, the average rating for NTLA stock is "Buy." The 12-month stock price forecast is $77.4, which is an increase of 161.22% from the latest price.Discover historical prices for NTLA stock on Yahoo Finance. View daily, weekly or monthly format back to when Intellia Therapeutics, Inc. stock was issued. Find the latest Intellia Therapeutics, Inc. NTLA analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range …Dec 1, 2023 · It's typically categorized as a valuation metric and is most often quoted as Cash Flow per Share and as a Price to Cash flow ratio. In this case, it's the cash flow growth that's being looked at ...

As of March 29, 2023, 4:00 PM CST, Intellia Therapeutics Inc’s stock price was $37.56. Intellia Therapeutics Inc is up 4.28% from its previous closing price of $36.02. During the last market session, Intellia Therapeutics Inc’s stock traded between $35.98 and $37.55. Currently, there are 81.26 million shares of Intellia Therapeutics Inc ...Intellia Therapeutics Inc’s Stock Price as of Market Close. As of March 22, 2023, 4:00 PM CST, Intellia Therapeutics Inc’s stock price was $37.15. Intellia Therapeutics Inc is down 6.63% from its previous closing price of $39.79. During the last market session, Intellia Therapeutics Inc’s stock traded between $38.25 and $39.94.14,305.03 +78.81(+0.55%) Russell 2000 +53.62(+2.96%) Crude Oil -1.56(-2.05%) Gold 2,091.00 +33.80(+1.64%) Advertisement Intellia Therapeutics, Inc. (NTLA) NasdaqGM - NasdaqGM Real Time Price....Instagram:https://instagram. aascxlng stockshow to buy bitcoins in cash appsp global stock Shares of Intellia Therapeutics, Inc. (NTLA) have gained 23.5% over the past four weeks to close the last trading session at $43.19, but there could still be a solid upside left in the stock if ... x stovkcoal stocks to buy View the latest Intellia Therapeutics Inc. (NTLA) stock price, news, historical charts, analyst ratings and financial information from WSJ. best wallet for nft Stock Price Forecast. The 8 analysts offering 12-month price forecasts for Caribou Biosciences Inc have a median target of 23.00, with a high estimate of 30.00 and a low estimate of 13.00. The ...Find the latest Intellia Therapeutics, Inc. (NTLA) stock forecast based on top analyst's estimates, plus more investing and trading data from Yahoo Finance